Perfect Fit for IFS: Safe Scalable CRISPR Medicine Using LgRNA

A Manufacturing and Control Strategy to Minimize Spacer Impurities and Enable Reliable Clinical Supply. 

 

LgRNA moves the critical control of spacer fidelity upstream to a short, readily purifiable fragment (<40nt) and decouples scaffold production from guide-specific synthesis. This architecture directly mitigates the spacer-impurity and lot-to-lot variability problems inherent in conventional long sgRNA, while remaining compatible with standard oligonucleotide quality requirements and enabling practical large-lot supply for rare-disease programs. The resulting product is both safer by design and more scalable.

Read more here.

This entry was posted in CRISPR Medicine Breakthrough, CRISPR-Based Therapeutics. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *